“Cost per Responder Analysis of Guselkumab Versus Certolizumab Pegol Using Efficacy Results from Pivotal Clinical Trials in Patients with Moderate to Severe Plaque Psoriasis”, J of Skin, vol. 2, p. S80, Dec. 2018, doi: 10.25251/skin.2.supp.81.